Exenatide, a glucagon-like peptide-1 (GLP-1) receptoragonist antidiabetic drug, has the capacity to overcome insulin resistance andattenuate hepatic steatosis but the specific underlying mechanism is unclear.This study was designed to investigate the underlying molecular mechanisms ofexenatide therapy on NAFLD. The gene discussed is GLP1R; the disease is Hepatic steatosis.